Literature DB >> 20694732

Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.

Barbra S Miller1, Paul G Gauger, Gary D Hammer, Thomas J Giordano, Gerard M Doherty.   

Abstract

PURPOSE: Various staging systems for adrenocortical carcinoma (ACC) have been proposed. We hypothesized that incorporating tumor grade into the current European Network for the Study of Adrenal Tumors (ENSAT) staging system would improve the ability to more accurately predict time to recurrence and death.
METHODS: A retrospective review of patients included in the University of Michigan ACC database from 2005 to 2009 was done; and stage, tumor grade, time to recurrence, and death were recorded and analyzed using the Cox regression and Kaplan-Meier survival curves.
RESULTS: Ninety one patients had complete information for inclusion. The median follow-up was 24 months while the median time to recurrence was 4.1 months. There were 28 deaths; overall, tumor grade showed a significant difference in time to tumor recurrence (p = 0.011) and time to death (p = 0.004). Time to death among stage 2 patients separated into those with high- and low-grade tumors reached statistical significance (p = 0.05), and notable but not statistically significant differences were identified in all stages. Based on tumor grade and survival curves, modifications to the current ENSAT staging system were made.
CONCLUSION: Tumor grade plays a significant role in the outcome of patients with ACC. High-grade tumors are associated with shorter disease-free intervals and shorter overall survival. The proposed modification of the ENSAT staging system allows for incorporation of tumor grade when predicting overall survival.

Entities:  

Mesh:

Year:  2010        PMID: 20694732     DOI: 10.1007/s00423-010-0698-y

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  25 in total

1.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy.

Authors:  Florence de Fraipont; Michelle El Atifi; Nadia Cherradi; Gwennaelle Le Moigne; Geneviève Defaye; Rémi Houlgatte; Jérôme Bertherat; Xavier Bertagna; Pierre-François Plouin; Eric Baudin; François Berger; Christine Gicquel; Olivier Chabre; Jean-Jacques Feige
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Laparoscopic resection of adrenal cortical carcinoma: a cautionary note.

Authors:  Ricardo J Gonzalez; Suzanne Shapiro; Nicholas Sarlis; Rena Vassilopoulou-Sellin; Nancy D Perrier; Douglas B Evans; Jeffrey E Lee
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

Review 3.  Adrenocortical cancer.

Authors:  Melissa Wandoloski; Kimberly J Bussey; Michael J Demeure
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

Review 4.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 5.  Adrenocortical cancer: pathophysiology and clinical management.

Authors:  Rossella Libè; Amato Fratticci; Jérôme Bertherat
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

6.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.

Authors:  Thomas J Giordano; Dafydd G Thomas; Rork Kuick; Michelle Lizyness; David E Misek; Angela L Smith; Donita Sanders; Rima T Aljundi; Paul G Gauger; Norman W Thompson; Jeremy M G Taylor; Samir M Hanash
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 7.  Molecular markers and the pathogenesis of adrenocortical cancer.

Authors:  Patsy S H Soon; Kerrie L McDonald; Bruce G Robinson; Stan B Sidhu
Journal:  Oncologist       Date:  2008-05

Review 8.  Clinical review: Adrenocortical carcinoma: clinical update.

Authors:  Bruno Allolio; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

9.  The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.

Authors:  Giovanni Lughezzani; Maxine Sun; Paul Perrotte; Claudio Jeldres; Ahmed Alasker; Hendrik Isbarn; Lars Budäus; Shahrokh F Shariat; Giorgio Guazzoni; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur J Cancer       Date:  2010-01-13       Impact factor: 9.162

10.  Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.

Authors:  J E Lee; D H Berger; A K el-Naggar; R C Hickey; R Vassilopoulou-Sellin; R F Gagel; M A Burgess; D B Evans
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  21 in total

Review 1.  Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Authors:  E Baudin; S Leboulleux; A Al Ghuzlan; C Chougnet; J Young; D Deandreis; F Dumont; F Dechamps; C Caramella; P Chanson; E Lanoy; I Borget; M Schlumberger
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

2.  Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma.

Authors:  Barbra S Miller; Kathleen M Ignatoski; Stephanie Daignault; Ceit Lindland; Megan Doherty; Paul G Gauger; Gary D Hammer; Stewart C Wang; Gerard M Doherty
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

3.  Surgical endocrinology--update 2010.

Authors:  Bruno Niederle
Journal:  Langenbecks Arch Surg       Date:  2010-08-16       Impact factor: 3.445

Review 4.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

6.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Authors:  Siyuan Zheng; Andrew D Cherniack; Ninad Dewal; Richard A Moffitt; Ludmila Danilova; Bradley A Murray; Antonio M Lerario; Tobias Else; Theo A Knijnenburg; Giovanni Ciriello; Seungchan Kim; Guillaume Assie; Olena Morozova; Rehan Akbani; Juliann Shih; Katherine A Hoadley; Toni K Choueiri; Jens Waldmann; Ozgur Mete; A Gordon Robertson; Hsin-Ta Wu; Benjamin J Raphael; Lina Shao; Matthew Meyerson; Michael J Demeure; Felix Beuschlein; Anthony J Gill; Stan B Sidhu; Madson Q Almeida; Maria C B V Fragoso; Leslie M Cope; Electron Kebebew; Mouhammed A Habra; Timothy G Whitsett; Kimberly J Bussey; William E Rainey; Sylvia L Asa; Jérôme Bertherat; Martin Fassnacht; David A Wheeler; Gary D Hammer; Thomas J Giordano; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

7.  A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.

Authors:  Caroline E Poorman; Cecilia G Ethun; Lauren M Postlewait; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solórzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2017-11-21       Impact factor: 5.344

8.  Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.

Authors:  Dipika R Mohan; Antonio Marcondes Lerario; Tobias Else; Bhramar Mukherjee; Madson Q Almeida; Michelle Vinco; Juilee Rege; Beatriz M P Mariani; Maria Claudia N Zerbini; Berenice B Mendonca; Ana Claudia Latronico; Suely K N Marie; William E Rainey; Thomas J Giordano; Maria Candida B V Fragoso; Gary D Hammer
Journal:  Clin Cancer Res       Date:  2019-02-15       Impact factor: 12.531

9.  Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.

Authors:  Jordan J Baechle; Paula Marincola Smith; Carmen C Solórzano; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason Prescott; Timothy Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Lawrence A Shirley; Ryan C Fields; Linda Jin; Daniel E Abbott; Sean Ronnekleiv-Kelly; Jason K Sicklick; Adam Yopp; John Mansour; Quan-Yang Duh; Natalie Seiser; Konstantinos Votanopoulos; Edward A Levine; George Poultsides; Colleen M Kiernan
Journal:  Ann Surg Oncol       Date:  2021-02-14       Impact factor: 5.344

10.  The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.

Authors:  Jiayu Liang; Zhihong Liu; Liang Zhou; Yongquan Tang; Chuan Zhou; Kan Wu; Fuxun Zhang; Fan Zhang; Xin Wei; Yiping Lu; Yuchun Zhu
Journal:  Endocrine       Date:  2019-11-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.